<DOC>
	<DOCNO>NCT00884819</DOCNO>
	<brief_summary>This prospective randomized , double-blind placebo-controlled trial 6 month ' duration evaluate effect fenofibrate ( 200 mg/day ) females polycystic ovary syndrome mild hypertriglyceridemia . The investigator primary objective determine whether fenofibrate reduce hepatic adiposity measure use MRI , secondary outcome delineate impact fenofibrate biochemical clinical parameter insulin resistance , cardiovascular disease , reproductive status .</brief_summary>
	<brief_title>Effects Fenofibrate Metabolic Reproductive Parameters Polycystic Ovary Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>premenopausal woman ≥ 18 year diagnosis PCOS base recent 2006 Androgen Excess Society criterion ( modify Rotterdam 2003 ) waist circumference &gt; 88 cm fast TG 2.0 5.0 mmol/L stable type oral contraceptive minimum 3months know contraindication MRI pregnancy , lactation , desire become pregnant participation another clinical trial fast TF level ≥ 5.0 mmol/L AST ALT &gt; 2.5 time upper limit normal ( ULN ) creatinine kinase ( CK ) &gt; 6x ULN creatinine &gt; 115 μmol/L fast glucose ≥ 7.0 mmol/L and/or 2h glucose post oral glucose tolerance test ( OGTT ) ≥ 11.1 mmol/L personal history DM2 personal history renal disease , liver disease ( except NAFLD ) , heart disease body mass index ( BMI ) &lt; 18 &gt; 40 kg/m² increase alcohol use ( &gt; 9 standard drink per week [ standard drink = 12oz beer , 5oz wine , 1.5oz spirit ] ) drug use use hormonal contraception , growth hormone , glucocorticoid , antidiabetic/antidyslipidemia medication , anabolic steroid .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>polycystic ovary syndrome</keyword>
	<keyword>hepatic adiposity</keyword>
	<keyword>diabetes</keyword>
	<keyword>hormone</keyword>
	<keyword>cardiovascular disease</keyword>
</DOC>